主动脉弓去分支联合胸主动脉腔内修复术治疗B型主动脉夹层
该回顾性多中心国际数据库研究纳入2005至2021年58例接受胸主动脉腔内修复术(TEVAR)的B型主动脉夹层患者,分析主动脉弓去分支的差异。左锁骨下动脉旁路择期施行(26%),发生1例卒中;另6例(10%)行更近端去分支,为死亡和支架数量的显著危险因素。再干预率和死亡率分别为17.2%(n=10)和29.3%(n=17)。
要点
- 左锁骨下动脉旁路择期施行占26%,发生1例卒中,可能为栓塞原因。
- 更近端主动脉去分支占10%,为死亡和支架数量的显著危险因素。
- 总体再干预率17.2%(n=10),死亡率29.3%(n=17)。
核心结论
- 主动脉弓去分支联合TEVAR治疗B型主动脉夹层与显著死亡率相关。
- 未来治疗主动脉弓病变可 incorporating 分支支架装置,以消除去分支需求、改善卒中率并减少未来再干预。
研究设计与样本
- 回顾性多中心国际数据库分析,纳入2005至2021年接受TEVAR的B型主动脉夹层患者58例。
- 采用IBM SPSS 26进行统计分析,生存率用Kaplan-Meier法计算,P值小于0.05认为有统计学意义。
主要发现
- 58例中27例(46.6%)为复杂性疾病,31例为简单性疾病,其中10例(17.2%)为高风险、21例(36.2%)为低风险。
- Zone 2为最常用的支架移植物近端锚定区。
- 左锁骨下动脉旁路择期施行占26%,发生1例卒中,可能为栓塞原因。
- 另6例(10%)在TEVAR前行更近端主动脉去分支,为死亡和支架数量的显著危险因素。
- 总体再干预率为17.2%(n=10),死亡率为29.3%(n=17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since its introduction, thoracic endovascular aortic repair (TEVAR) has revolutionized the treatment of type B aortic dissections (TBADs). However, the proximal aspect of the aortic pathology treated may infringe on the origin of the left subclavian artery or even more proximally. Hence, to ensure durable outcomes, the origin of these vessels needs to be covered, but an extra-anatomical bypass is required to perfuse vital branches, known as aortic arch debranching. This series aims to describe and delineate the disparities of aortic arch debranching during TEVAR for TBAD. METHODS: A retrospective review and analysis of a multicenter international database was conducted to identify patients with TBAD treated with TEVAR between 2005 and 2021. Data analyzed included patient demographics, disease characteristics, operative characteristics, and postoperative outcomes with follow-up on mortality and reintervention. All statistical analyses were carried out using IBM SPSS 26. Patient survival was calculated using a Kaplan-Meier survival analysis, and a P value of less than 0.05 was considered statistically significant. RESULTS: A total of 58 patients were included in the analysis, of which 27 (46.6%) presented with complicated disease and 31 were uncomplicated, of which 10 (17.2%) were classed as high risk and 21 (36.2%) low risk. Zone 2 was the most common proximal landing zone for the stent graft. Left subclavian artery bypass was performed selectively (26%), with 1 stroke occurring, likely due to embolic reasons. A further 6 underwent more proximal aortic debranching before TEVAR (10%) and was a significant risk factor for mortality and the number of stents deployed. The overall rates of reintervention and mortality were 17.2% (n = 10) and 29.3% (n = 17). CONCLUSIONS: Aortic arch debranching and TEVAR for TBAD is associated with significant mortality. Future developments to treat aortic arch pathology could incorporate branched graft devices, eliminating the need for debranching, improving stroke rates, and reducing future reinterventions.
引用
- Bashir M, Jubouri M, Surkhi AO, et al. Aortic Arch Debranching and Thoracic Endovascular Aortic Repair (TEVAR) for Type B Aortic Dissection. Ann Vasc Surg. 2023. PMID: 37866676. doi:10.1016/j.avsg.2023.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。